Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Aditxt Inc ADTX

Healthcare Biotechnology
Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women’s health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.


NDAQ:ADTX - Post by User

Aditxt Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
  • PressReleaseX
Post by PressReleaseon Oct 21, 2022 9:02am
64 Views
Post# 35038407

New Press Release - Aditxt's (Nasdaq: ADTX) Adimune(TM) Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI(TM)-100 in Preparation for Planned Psoriasis First-in-Human Trials

New Press Release - Aditxt's (Nasdaq: ADTX) Adimune(TM) Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI(TM)-100 in Preparation for Planned Psoriasis First-in-Human Trials
Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces that its program Adimune™ has initiated the GMP manufacturing of drug candidate ADI™-100...read article.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities